ArticleJACC. Case reports2026
Probable Antiphospholipid Syndrome Causing Biventricular Thrombi and Cardiogenic Shock.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntracardiac thrombi are a rare manifestation of antiphospholipid syndrome (APS), with biventricular involvement being exceedingly uncommon. CASE SUMMARY: A 70-year-old woman with recent Takotsubo cardiomyopathy was admitted with cardiogenic shock. Imaging demonstrated large biventricular thrombi. Initial laboratory testing was consistent with probable APS. Inotropic support and anticoagulation were initiated. After failed attempts to wean inotropes, the patient elected hospice care. DISCUSSION: This case highlights the diagnostic uncertainty and limited evidence guiding management of extensive intracardiac thrombosis in patients with suspected APS presenting with cardiogenic shock. Beyond anticoagulation, the evidence base for managing intracardiac thrombi in probable APS is limited to case reports, and there are large risks associated with invasive strategies for removing intracardiac thrombi. TAKE-HOME MESSAGES: Rapid development of extensive multichamber intracardiac and systemic thrombosis should prompt evaluation for APS. Anticoagulation remains the cornerstone of therapy; evidence guiding invasive strategies is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.